Reicin Glenn 4

What Happened

• Glenn Reicin, Chief Financial Officer of Harmony Biosciences (HRMY), received a derivative stock award reported as 164,309 underlying shares on April 14, 2026. The award is shown at $0.00 per share on the Form 4, indicating a grant of equity (e.g., stock options or restricted stock units), not an open‑market purchase or sale.

Key Details

• Transaction date: April 14, 2026; Form 4 filed: May 18, 2026 (filed ~34 days after the transaction).
• Transaction type/code: A (award/grant/acquisition); reported as derivative—164,309 shares @ $0.00.
• Vesting (per footnote): 25% vests on April 14, 2027, with the remainder vesting ratably on a quarterly basis through the fourth anniversary of the grant, subject to continued service.
• Shares owned after transaction: not specified in the provided excerpt.
• No 10b5‑1 plan, tax‑withholding sale, or immediate sale reported in the excerpt.

Context

• This is a compensation award, not an immediate market purchase or sale. Because the award vests over time, it does not represent immediately realizable stock ownership; any future exercise or sale would be reported separately. The Form 4 for this transaction was filed more than a month after the grant date; Form 4s are typically due within two business days of the transaction, so the late filing may warrant attention but can result from administrative delay or correction.